New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
07:22 EDTGSK, NVS, BAX, UTHR, BIIB, SQNM, NVOCaSA-ISPE to hold a conference
21st Annual Lilfe Sciences Technology Conference is being held in Raleigh, North Carolina on April 8.
News For BIIB;NVS;NVO;UTHR;GSK;SQNM;BAX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
November 25, 2015
11:29 EDTNVS, GSKStudy says Valeant, others exploding dermatology drug prices, WSJ reports
The JAMA Dermatology journal published a new study that found that retail prices of 19 dermatologic prescription drugs increased fivefold on average between 2009 and 2015, reported The Wall Street Journal. Targretin, marketed by Valeant (VRX), jumped to $30,320 this year from $15,708 last year and $1,687 in 2009, the study found, but "It's not just Valeant," said lead author Miranda Rosenberg. Prices for drugs made by GlaxoSmithKline (GSK) and Novartis (NVS) at least doubled or tripled over the same time frame, the report noted. Reference Link
November 24, 2015
17:51 EDTNVSFDA approves first seasonal influenza vaccine containing an adjuvant
The U.S. FDA approved Fluad, the first seasonal influenza vaccine containing an adjuvant. Fluad, a trivalent vaccine produced from three influenza virus strains (two subtype A and one type B), is approved for the prevention of seasonal influenza in people 65 years of age and older. Fluad and Agriflu are manufactured by Novartis Vaccines and Diagnostics Limited, an affiliate of Novartis Vaccines and Diagnostics, based in Cambridge, Massachusetts. Reference Link
11:16 EDTGSKAdaptimmune initiates Phase I/II trial of affinity enhanced T-cell therapy
Subscribe for More Information
10:06 EDTNVSHigh option volume stocks
High option volume stocks: BDBD UNXL NVS SEDG BLOX GPRE SIG BPL TIF DY
05:34 EDTBIIBSobi, Biogen announce approval of Elocta in Europe
Subscribe for More Information
05:25 EDTNVSNovartis receives EU approval for Entresto
Novartis announced that the European Commission has approved Entresto for the treatment of adult patients with symptomatic chronic heart failure with reduced ejection fraction. Entresto is a twice a day tablet and has a unique mode of action which is thought to reduce the strain on the failing heart.
November 23, 2015
08:08 EDTGSKIdera Pharmaceuticals announces partnership with GSK
Idera Pharmaceuticals (IDRA) announced it has entered into an exclusive worldwide collaboration and license agreement with GSK (GSK) to research, develop and commercialize selected molecules from Idera's 3rd generation antisense platform for the treatment of selected targets in renal disease. Under the terms of the agreement, Idera is eligible to receive approximately $100M in development and regulatory milestone payments, including a $2.5M upfront payment. Additionally, Idera is eligible to receive royalties on all sales upon commercialization at varying rates up to five percent on annual net sales in excess of $500M.
05:37 EDTNVSNovartis receives two EU approvals for Cosentyx
Novartis announced today that the European Commission has approved Cosentyx for the treatment of people living with ankylosing spondylitis, or AS, and psoriatic arthritis, or PsA. For AS, this is the first new treatment advance in 16 years since the development of the current standard of care, anti-tumor necrosis factor, or anti-TNF, therapy. Cosentyx is the first in a new class of medicines called interleukin-17A, or IL-17A, inhibitors to be made available in Europe for AS and PsA. These approvals follow on from the earlier EC approval of Cosentyx for the first-line treatment of patients with moderate-to-severe plaque psoriasis. AS and PsA are common inflammatory joint conditions affecting approximately five million people in Europe, yet they remain significantly under-diagnosed and under-treated. If not treated effectively, they can lead to irreversible damage to the spine and joints, causing life-long pain and disability. New treatments are urgently needed for both conditions as many patients do not respond well to existing treatments, with up to 40% not responding sufficiently to anti-TNFs.
November 20, 2015
17:16 EDTNVSNovartis announces FDA approval of Tafinlar + Mekinist
Subscribe for More Information
14:41 EDTNVSNY AG leads team of states in $390M settlement with Novartis over kickbacks
Subscribe for More Information
14:00 EDTNVSNY AG leads team of states in $390M settlement with Novartis over kickbacks
Subscribe for More Information
10:52 EDTNVSFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
07:17 EDTBIIBBiogen says Benepali receives 'positive' opinion from CHMP
Subscribe for More Information
November 18, 2015
08:11 EDTGSK, NVSIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information
07:43 EDTNVSJefferies to hold a conference
Subscribe for More Information
November 17, 2015
16:38 EDTNVSAduro Biotech to delay filing 10-Q
Subscribe for More Information
07:34 EDTNVSOphthotech to hold a conference call
Subscribe for More Information
06:08 EDTNVSRoche subsidiary to participate in Ophthotech and Novartis agreement
Subscribe for More Information
05:24 EDTNVSNovartis announces Phase III FLAME head-to-head trial met primary endpoint
Subscribe for More Information
November 16, 2015
06:11 EDTBAXBaxter resumed with a Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst Brooks West downgraded Baxter (BAX) to Neutral after resuming coverage of the name. The company, post the spin of Baxalta (BXLT), "has a number of moving pieces that need to be addressed," West tells investors in a research note. He lowered his price target for shares to $39 from $90.
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use